{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:07:38Z","timestamp":1794938858025,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The lack of validated tools to predict rheumatoid arthritis (RA) disease course warrants the development of new reliable biomarkers. Our aim was to evaluate the merit of circulating SEMA4A for the prediction of outcomes in patients with RA. In a first cohort of 101 consecutive RA patients followed up for 41\u2009\u00b1\u200915\u00a0months, increased baseline SEMA4A levels were identified as an independent predictor of treatment failure (hazard ratio, HR 2.71, 95% CI 1.14\u20136.43), defined by the occurrence of patient-reported flares and initiation or change of targeted therapy. The highest predictive value of treatment failure was obtained with the combination of increased circulating SEMA4A and\/or Disease Activity Score (DAS) 28-CRP\u2009&gt;\u20093.2 and\/or active synovitis on doppler ultrasound (HR 10.42, 95% CI 1.41\u201376.94). In a second independent cohort of 40 consecutive RA patients who initiated new therapy because of insufficient disease control, baseline SEMA4A levels were significantly higher in patients who further experienced none or moderate response, and SEMA4A concentrations were markedly decreased in the group of patients with good clinical response as compared to non-responders. Circulating SEMA4A appears as an appealing biomarker in RA with ability to predict treatment failure, and with association with response to therapy.<\/jats:p>","DOI":"10.1038\/s41598-023-41943-3","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:01:57Z","timestamp":1693897317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment"],"prefix":"10.1038","volume":"13","author":[{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elo\u00efse","family":"Vandebeuque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Combier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Poiroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Steelandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Boisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"41943_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers. 4, 18001 (2018).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"41943_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/art.38323","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon, D. H. et al. Review: Treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis?. Arthritis Rheumatol. 66, 775\u2013782 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"41943_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"41943_CR4","volume":"13","author":"SC Shapiro","year":"2021","unstructured":"Shapiro, S. C. Biomarkers in rheumatoid arthritis. Cureus. 13(5), e15063 (2021).","journal-title":"Cureus."},{"key":"41943_CR5","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1186\/ar4469","volume":"16","author":"J Kay","year":"2014","unstructured":"Kay, J. et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: Acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res. Ther. 16, R40 (2014).","journal-title":"Arthritis Res. Ther."},{"issue":"17","key":"41943_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13075-015-0734-y","volume":"25","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Expression of Semaphorin 4A and its potential role in rheumatoid arthritis. Arthritis Res. Ther. 25(17), 227 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"41943_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/art.41701","volume":"73","author":"J Avouac","year":"2021","unstructured":"Avouac, J. et al. Semaphorins: From angiogenesis to inflammation in rheumatoid arthritis. Arthritis Rheumatol. 73, 1579\u20131588 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"41943_CR8","doi-asserted-by":"publisher","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","volume":"3","author":"MA D'Agostino","year":"2017","unstructured":"D\u2019Agostino, M. A. et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: Definition and development of a standardised, consensus-based scoring system. RMD Open 3, e000428 (2017).","journal-title":"RMD Open"},{"key":"41943_CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/ijms22010021","volume":"22","author":"T Carvalheiro","year":"2020","unstructured":"Carvalheiro, T. et al. Semaphorin4A-Plexin D1 axis induces Th2 and Th17 while represses Th1 skewing in an autocrine manner. Int. J. Mol. Sci. 22, 21 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"41943_CR10","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.7150\/thno.54023","volume":"11","author":"R Mastrantonio","year":"2021","unstructured":"Mastrantonio, R., You, H. & Tamagnone, L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 11, 3262\u20133277 (2021).","journal-title":"Theranostics."},{"key":"41943_CR11","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3899\/jrheum.171375","volume":"45","author":"K Bechman","year":"2018","unstructured":"Bechman, K. et al. Flares in rheumatoid arthritis patients with low disease activity: Predictability and association with worse clinical outcomes. J. Rheumatol. 45, 1515\u20131521 (2018).","journal-title":"J. Rheumatol."},{"key":"41943_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3899\/jrheum.190760","volume":"47","author":"D Kuettel","year":"2020","unstructured":"Kuettel, D. et al. Pain and self-reported swollen joints are main drivers of patient-reported flares in rheumatoid arthritis: Results from a 12-month observational study. J. Rheumatol. 47, 1305\u20131313 (2020).","journal-title":"J. Rheumatol."},{"key":"41943_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13075-019-2064-y","volume":"21","author":"EC de Moel","year":"2019","unstructured":"de Moel, E. C. et al. Circulating calprotectin (S100A8\/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Res. Ther. 21, 268 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"41943_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/rheumatology\/keaa258","volume":"60","author":"J Ramirez","year":"2021","unstructured":"Ramirez, J. et al. Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: A 5 year follow-up study. Rheumatology 60, 667\u2013674 (2021).","journal-title":"Rheumatology"},{"key":"41943_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/rheumatology\/kex003","volume":"56","author":"CAM Bouman","year":"2017","unstructured":"Bouman, C. A. M. et al. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: Predictive value for clinical and radiographic outcomes. Rheumatology 56, 973\u2013980 (2017).","journal-title":"Rheumatology"},{"key":"41943_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192425","volume":"13","author":"M Ghiti Moghadam","year":"2018","unstructured":"Ghiti Moghadam, M. et al. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS ONE 13, e0192425 (2018).","journal-title":"PLoS ONE"},{"key":"41943_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DM van der Heijde","year":"1990","unstructured":"van der Heijde, D. M. et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann. Rheum. Dis. 49, 916\u2013920 (1990).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41943-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:17:03Z","timestamp":1700493423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41943-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41943"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-41943-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1767575\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1767575\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14626"}}